To include your compound in the COVID-19 Resource Center, submit it here.

AZD1775: Phase II data

An open-label, international, 2-part Phase II trial in 121 patients with platinum-sensitive, p53-mutated ovarian cancer showed that twice-daily

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE